

U.S. SERIAL NO.: 08/458,978
FILED: June 2, 1995
AMENDMENT

B¹
cells are provided in an amount effective to inhibit smooth muscle cell proliferation at the
site of the injury ~~without migration of the~~ ^{vascular} endothelial cells ^{endothelial cell of the blood vessel} to the ~~arterial lining~~.

B²
3. (twice amended) The method of claim 1 wherein the matrix is in a form
selected from the group consisting of gels [or] , foams, suspensions, microcapsules, solid
polymeric supports, [or] and fibrous structures.

B³
6. (twice amended) The method of claim 5 wherein the matrix is formed of a
material selected from the group consisting of polyhydroxy acids, polyorthoesters,
polyanhydrides, proteins, ~~carbohydrates~~ [or] ~~and~~ polysaccharides, polyphosphazenes,
polyalkylene oxides and combinations thereof.

C B⁴
8. (twice amended) The method of claim 1 wherein the matrix further
comprises biologically active compounds selected from the group consisting of [,]
prostaglandins, prostanoids, [compounds regulating the renin-angiotensin axis,] tyrosine
kinase inhibitors, immunosuppressants, glucocorticoids, anti-oxidants, free radical
scavengers, peptide hormones, angiogenic ^{factors,} ~~and~~ angiogenic inhibitory factors, and
combinations thereof.

C
S
B
C
11. (twice amended) A composition for inhibiting mechanisms involved in
restenosis of a blood vessel ^{having an endothelial cell lining} ~~following injury to vascular tissue~~ ^{the endothelial cell lining} of the blood vessel in a patient
in need of treatment thereof, comprising a biocompatible matrix shaped for implantation
adjacent to a blood vessel, the matrix having seeded therein or thereon dissociated ^{vascular} endothelial
cells, wherein ^{vascular} the endothelial cells are in an amount effective to inhibit smooth muscle cell

U.S. SERIAL NO.: 08/458,978

FILED: June 2, 1995

AMENDMENT

B₁ proliferation at the site of the injury ^{vascular} without migration of the ^{endothelial cell} ~~endothelial cell~~ to the ~~arterial~~ ^{of the blood vessel} lining.

B₆ 13. (twice amended) The composition of claim 11 wherein the matrix is in a form selected from the group consisting of gels [or], foams, suspensions, microcapsules, solid polymeric supports, [or] and fibrous structures.

B₇ 14. (amended) The composition of claim 11 wherein the cells are selected from the group consisting of autologous cells, allograft cells, and xenograft cells[, and genetically engineered cells].

B₈ 16. (twice amended) The composition of claim 15 wherein the matrix is formed of a material selected from the group consisting of polyhydroxy acids, polyorthoesters, polyanhydrides, proteins, ~~carbohydrates~~ [or], polysaccharides, polyphosphazenes, and combinations thereof.

B₉ 18. (twice amended) The composition of claim 11 wherein the matrix further comprises biologically active compounds selected from the group consisting of prostaglandins, prostanoids, [compounds regulating the renin-angiotensin axis,] tyrosine kinase inhibitors, immunosuppressants, glucocorticoids, anti-oxidants, free radical scavengers, peptide hormones, angiogenic ^{factors;} ~~and~~ angiogenic inhibitory factors ^{and combinations thereof}.

B₁₀ Please add new claim 20.

B₁₀ 19. ~~20.~~ (new) The composition of claim 14 wherein the cells are genetically engineered.